Tag Archives: Mayank Mamtani

B.Riley FBR Thinks Viking Therapeutics’ Stock is Going to Recover

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $16. The company’s shares closed yesterday at $7.57, close to its 52-week low of

B.Riley FBR Keeps a Buy Rating on Medicines Co (MDCO)

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Medicines Co (MDCO – Research Report) today and set a price target of $61. The company’s shares closed yesterday at $36.52. Mamtani commented: “The Medicines Company (MDCO) remains the most

B.Riley FBR Sticks to Its Buy Rating for Dicerna Pharma (DRNA)

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Dicerna Pharma (DRNA – Research Report), with a price target of $24. The company’s shares closed yesterday at $14.78. Mamtani said: “Pharmaceuticals, Inc. (DRNA) disclosed

B.Riley FBR Thinks Akari Therapeutics’ Stock is Going to Recover

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Akari Therapeutics (AKTX – Research Report) today and set a price target of $7. The company’s shares closed yesterday at $2.07, close to its 52-week low of $1.56. Mamtani observed:

B.Riley FBR Thinks Genfit SA’s Stock is Going to Recover

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $52. The company’s shares closed yesterday at $20.58, close to its 52-week low of $20.12. Mamtani said:

Allena Pharmaceuticals Inc (ALNA) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Allena Pharmaceuticals Inc (ALNA – Research Report) on May 20 and set a price target of $22. The company’s shares closed yesterday at $5.06, close to its 52-week low of